Bloomberg reports that Allergan has pursued Sanofi and Johnson & Johnson to partner up and help the company avoid being absorbed by Valeant.

Valeant’s $45.7-billion bid is its second offer, and one which Bloomberg noted that Allergan has not yet responded to. According to the news service, it’s not clear if Sanofi or J&J have said they are interested in the Botox maker.